GlaxoSmithKline, Nabi to Develop Smoking Vaccine

GlaxoSmithKline PLC and Nabi Biopharmaceuticals said they will work together to develop vaccines to help smokers give up the habit, in a deal that could be worth more than $500 million.
The Seattle Times